Plasmid expression vectors were constructed that contained the genes encoding herpes simplex virus 1 (HSV-1) glycoproteins C (gC), D (gD), and E (gE). Mice receiving two intramuscular injections of expression plasmid (50 mg) produced a specific HSV-1 antibody response. Mice receiving the gD plasmid were protected against a lethal intraperitoneal challenge of HSV-1 (5 1 10 4 pfu) but not against more demanding challenge doses. Protection with gC or gE plasmid vaccination could be demonstrated only if the inoculating dose of DNA was increased to 250 mg. In contrast, all mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge. Analysis of the HSV-1 antibody isotype produced by plasmid immunization revealed a response dominated by IgG2a. Combination delivery of all three glycoprotein expression plasmids provided better protection against lethal challenge, but mice receiving the combination were still not able to withstand increased challenge doses of virus.
Most vaccine strategies for herpes simplex virus (HSV) have virus such as HSV, which codes for ú75 different proteins, will require both cellular and humoral immune responses to focused on the development of subunit vaccines that consist of one or more of the HSV glycoproteins. Vaccination of mice multiple viral antigens. DNA vaccines have several potential advantages as subunit with purified glycoprotein D (gD) provides protection against a lethal intraperitoneal (ip) challenge of HSV, and vaccination vaccines. These include the elimination of time-consuming purification of recombinant proteins, the ability to stimulate both of guinea pigs with recombinant gD or gB protects against intravaginal HSV-2 infection [1, 2] . To date, clinical trials cell-mediated and humoral immunity, and the perceived safety advantages of subunit vaccines over live vaccines (for recent indicate that purified gD has induced neutralizing antibody responses in previously uninfected persons and boosted the reviews, see [5, 6] ). For complex pathogens, direct inoculation of plasmid DNA encoding viral antigens also offers an efficient antibody response in patients with genital herpes [3] . However, a clinical trial designed to determine the efficacy of a therapeumeans by which to evaluate multiple potential genes for their inclusion in a subunit vaccine [7] . tic vaccine in patients with genital herpes found only a modest effect on the frequency of HSV recurrences [4] , and there is Several reports have now described the use of plasmid DNAs encoding herpesvirus proteins to evoke a protective immune no evidence yet to indicate that gD is effective as a prophylactic vaccine. These vaccines may be less than ideal for either preresponse in animal models. Plasmid expression of HSV-1 gB or ICP27 protected mice against HSV challenge in a zosterivention or therapy against genital HSV infection in humans for several reasons. First, effective resolution of viral infection form model of recrudescence [8, 9] , and expression of HSV-1 gD protected mice against lethal ip challenge and inand control of virus spread after reactivation from latency requires an efficient cell-mediated immune response that may duced low levels of neutralizing antibody [10] . Immunization with plasmids encoding HSV-2 gD or a truncated form of gB not be stimulated by protein subunit vaccines. Second, it is quite likely that a successful immune response to a complex protected mice and guinea pigs from vaginal challenge with HSV-2 [11 -13] . However, it is not yet clear which viral antigens would be most effective in formulation of a candidate vaccine, and it seems likely that many candidate viral genes will need to be evaluated individually and in combination. JID 1998; 178 (September) mentary to the 5 and 3 ends of the coding sequence. Each gene were determined in separate experiments using a panel of myeloma proteins with known heavy-and light-chain compositions. For was initially cloned into a TA cloning vector (pCRII; Invitrogen, San Diego) and then into a eukaryotic plasmid expression vector color development, ABTS peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added; the reaction that uses the cytomegalovirus immediate-early promoter for expression (Invitrogen; pcDNA I for gD and pRc/CMV for gC and was stopped at 30 min by the addition of 1.5% KFl (in H 2 O), and the optical density (OD) was determined at 405 nm (reference OD gE). Construction of each plasmid vector was verified by restriction enzyme analysis and partial DNA sequencing of both the 5 and Å 490 nm). End-point titer was defined as the highest dilution of serum that gave an A 405 value that was 2-fold greater than that of 3 ends of the glycoprotein reading frame. In vitro expression of the specific HSV-1 glycoprotein was verified by transfection of the matched dilution of normal prebleed mouse serum and was also ú0.050. The sensitivity of the ELISA for HSV-1 glycoproVero cells with the appropriate expression plasmid followed by Western blotting and/or immunohistochemical staining. Routine teins was confirmed using monoclonal antibodies for gD, gE (Advanced Biotechnologies, Columbia, MD), and gC (Biodesign Interprocedures were used for PCR, cloning, and DNA sequencing [14] . Large amounts of plasmid DNA were prepared using Qiagen national, Kennebunk, ME 
Results
BALB/cByJ mice were purchased from Jackson Laboratories (Bar Harbor, ME) and used at 6-12 weeks of age. All mice were housed the specific antibody response; no advantage was conferred by Lennette [16] . Mean time to death (days) was calculated by arithwaiting 6 weeks for a second injection of plasmid DNA; and metic mean { SD for all mice within a group that died; surviving a third injection of plasmid DNA resulted in a still higher mice were not included in this calculation. The statistical signifiantibody titer but did not lead to increased protection against cance of differences in mean time to death were assessed using a lethal ip viral challenge of Ç10 LD 50 s (data not shown).
Student's t test.
Therefore, we selected two injections of plasmid DNA given HSV glycoprotein ELISA. HSV glycoproteins were purified Figure 1 . HSV glycoprotein antibody titers in sera of mice inoculated with glycoprotein D (gD) expression plasmid. Mice were inoculated 2 times (3 weeks apart) with indicated amount of gD expression plasmid. Pooled sera from groups of 5 mice were assayed for HSV-specific antibody using HSV glycoprotein ELISA.
and 10 mg did not (figure 1). To further characterize and comisotypes of glycoprotein-specific antibodies, and therefore, im inoculation was studied in subsequent experiments. pare the nature of the elicited antibody response, we analyzed the sera from the HSV-1 antibody -positive groups of mice for
To assess the strength of protection afforded by plasmid vaccination, mice were inoculated with gD expression plasmid their isotype specificity. In this experiment, all 3 dosage groups contained IgG2a-specific gD antibody with titers of 1:160 for (two im injections of 50 mg, 3 weeks apart) and challenged ip with 10-fold and 100-fold higher doses of HSV-1 McKrae (5 the 25-mg group, 1:160 for the 50-mg group, and 1:320 for the 100-mg group. Mice in the 50-and 100-mg groups also had 1 10 5 and 5 1 10 6 pfu, respectively). All mice died from these higher challenge doses, and there was no significant extension IgG2b antibody with titers of 1:320 and 1:80, respectively, and mice in the 100-mg group also further had IgG1 antibody at a of the mean time to death compared with that of the plasmidimmunized groups (data not shown). Thus, DNA immunization titer of 1:80. The sera from these 3 groups of mice contained neutralizing antibody at titers of 1:4 for the 25-mg group, 1:16 protects against a lethal challenge of 5 1 10 4 pfu but not against more demanding challenge doses. Indeed, survival of mice for the 50-mg group, and 1:64 for the 100-mg group.
Plasmid-immunized and control mice (from experiments challenged with this dose of virus ranged from 20% to 100% in repeated experiments (mean Å 63%), indicating the variabilshown in figure 1) were then challenged by ip injection of HSV-1 McKrae. As shown in figure 2 , all of the control immuity of the protective response. In addition, we compared the isotype profiles of the antibody nized mice died within 9 days of challenge; none of the mice that had received 50 mg of gD plasmid DNA died over the response to 2 injections of 50 mg of gD plasmid in multiple experiments ( figure 3 ). While IgG2a of relatively similar course of the experiment (ú25 days after challenge). Some mice that received 1 mg or 25 mg of plasmid DNA survived amounts was detected in all experiments, the titers of the other subclasses were quite variable. These results further underscore challenge, but most died, with a mean time to death similar to that of the control group. Of interest, 2 mice from the 100-mg the variability of the response to im plasmid vaccination.
Immunization of mice with gC and gE expression plasmids. group also died after challenge, although later than mice from the control group.
Plasmids expressing either HSV-1 gC or gE were also evaluated for their ability to elicit HSV-1 -specific antibody. Mice In addition to intramuscular (im) plasmid administration, several other routes of plasmid delivery were studied, including were injected with two 50-mg doses of either plasmid, and the sera were evaluated by ELISA. Low titers of HSV-1 -specific intradermal (id) and intravenous. HSV-1 -specific antibody was detected in mice inoculated by all three routes, and all 3 showed antibody were detected, but the sera were not neutralizing (table  2) . To determine whether the low antibody titers to these two some degree of protection. Comparison of id versus im delivery of gD expression plasmid was studied in some detail (table 1) . viral glycoproteins was an inherent characteristic of the antigens themselves, vaccinia vectors expressing HSV-1 gC or gE Injection via either route resulted in HSV-1 -specific antibody and afforded similar levels of protection. In repeated experiwere also used to vaccinate mice. Infection with 5 1 10 7 pfu of either vaccinia vector resulted in a substantial HSV-1 -specific ments, im and id inoculation resulted in similar quantities and / 9d50$$se27 08-03-98 13:12:49 jinfa UC: J Infect antibody response, although only the vaccinia-gC -infected (figure 4). In contrast, vaccinia vectors expressing either gC or gE protected 100% of mice that were challenged ip with a group produced detectable neutralizing antibody (table 2) . Isotyping of sera from mice injected twice with 50 mg of gC similar dose of HSV-1 (table 2) . Inoculation of mice with combinations of glycoprotein explasmid detected IgG2a and IgG2b antibody (1:320 each) and low titers of IgG1 and IgG3 (table 2) .
pression plasmids. Since all three glycoprotein expression plasmids elicited a specific antibody response when injected 2 Although two injections of 50 mg of gC or gE plasmid produced a detectable antibody response, this was not sufficient times at a 50-mg dose, it was of interest to determine whether vaccination with a combination of the three expression plasto provide protection against a lethal ip challenge of HSV-1 (table 2, figure 4) . However, protection could be achieved if mids would provide greater protection than any individual plasmid. Mice were therefore inoculated two times with a mixture mice were inoculated twice with 250 mg of plasmid DNA of all three plasmid DNAs (50 mg each). Isotyping of sera from mice injected with the combination of plasmids indicated predominately IgG2a antibody to HSV glycoproteins (data not However, since the ideal HSV subunit candidate is not known, Dose-response experiments indicated that as little as two injections of 25 mg of gD plasmid, given 3 weeks apart, elicited a DNA delivery may be an efficient way to screen multiple potential gene products for inclusion in either a traditional subunit specific antibody response. We were not able to detect HSV-1 antibody when lower amounts of plasmid were used, and for vaccine or a DNA vaccine. As an initial step in this evaluation and screening process, we characterized and compared the antipractical reasons, most of our experiments used two 50-mg doses of expression plasmid. It might be possible to enhance the imbody responses to three different HSV glycoproteins expressed mune response to lower doses of plasmid DNA either by use by DNA vaccination and evaluated the protective capacity obof a gene gun for immunization [18] or by pretreatment of tained by codelivery of all three expression plasmids. muscle with bupivacaine [19] . Both techniques have been reThe im inoculation of mice with plasmids expressing HSVported to increase plasmid DNA uptake by muscle cells. 1 gD, gC, or gE resulted in a specific HSV-1 antibody response.
It has been demonstrated [11] that two im injections of only 0.8 mg of a gD-2 expression plasmid induce a detectable antibody tory to different degrees [20] .
/ 9d50$$se27 08-03-98 13:12:49 jinfa UC: J Infect Although the majority of our experiments utilized im injecever, IgG1 was also sometimes detected, as was IgG2b ( figure  3) . In a more limited number of id delivery experiments, both tion of plasmid DNA, we found that other routes of delivery IgG1 and IgG2a were detected. Therefore, in contrast to previwere also effective in eliciting an antibody response, as has ous results, we did not observe a shift in the isotype profile been reported for plasmid delivery of other antigens [18, 21] .
following different routes of DNA delivery. A recent study reported that im injection of plasmid expression HSV gC and gE also represent good candidate antigens for vector resulted in a predominately IgG2a antibody response, vaccines. gC is involved in the initial interaction of the virus whereas id or gene-gun delivery resulted in a predominately with the cell [23] and in immune evasion by binding the C3b IgG1 response [22] 
